Evidence map›Paper›PMID 33466745›Full record

ArticleCancers2021

Synergism of Proneurogenic miRNAs Provides a More Effective Strategy to Target Glioma Stem Cells.

Adam Kosti, Rodrigo Barreiro, Gabriela D A Guardia, Shiva Ostadrahimi, Erzsebet Kokovay, Alexander Pertsemlidis, Pedro A F Galante, Luiz O F Penalva

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.7field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. LncRNACancer management and research · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Adam KostiGreehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
Rodrigo BarreiroGreehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
Gabriela D A GuardiaCentro de Oncologia Molecular, Hospital Sirio-Libanes, São Paulo 01308-060, Brazil.ORCID 0000-0002-1789-2768
Shiva OstadrahimiGreehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
Erzsebet KokovayDepartment of Cell Systems & Anatomy, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
Alexander PertsemlidisGreehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.ORCID 0000-0003-1624-9372
Pedro A F GalanteCentro de Oncologia Molecular, Hospital Sirio-Libanes, São Paulo 01308-060, Brazil.
Luiz O F PenalvaGreehey Children's Cancer Research Institute, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA.
The University of Texas Health Science Center at San Antonio · USHospital Sírio-Libanês · BRUniversidade de São Paulo · BR

Funding

TISSUE CULTURE---COREP30CA054174 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI Robin Jean Leach · 1991 to 2026
$59.1M
Computational Methods for Deep Sequencing Based RBP Binding Motif CharacterizatioR01HG006015 · NHGRI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI PENALVA, LUIZ OTAVIO, SMITH, ANDREW DAVID · 2011 to 2017
$2.6M
High Throughput DNA Sequencer: Illumina HiSeq 3000 SequencerS10OD021805 · OD · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI LAI, ZHAO · 2016 to 2016
$600k
Musashi1 and miR-137 antagonism: impact on neurogenesis and diseasesR21NS113344 · NINDS · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI KOKOVAY, ERZSEBET, PENALVA, LUIZ OTAVIO · 2020 to 2020
$425k
NCI NIH HHS P30 CA054174NHGRI NIH HHS R01 HG006015NIH HHS 1 R21 NS113344-01A1NIH HHS S10 OD021805NINDS NIH HHS R21 NS113344Owens Foundation NA
6 · The paper itself

Abstract

Tumor suppressor microRNAs (miRNAs) have been explored as agents to target cancer stem cells. Most strategies use a single miRNA mimic and present many disadvantages, such as the amount of reagent required and the diluted effect on target genes. miRNAs work in a cooperative fashion to regulate distinct biological processes and pathways. Therefore, we propose that miRNA combinations could provide more efficient ways to target cancer stem cells. We have previously shown that miR-124, miR-128, and miR-137 function synergistically to regulate neurogenesis. We used a combination of these three miRNAs to treat glioma stem cells and showed that this treatment was much more effective than single miRNAs in disrupting cell proliferation and survival and promoting differentiation and response to radiation. Transcriptomic analyses indicated that transcription regulation, angiogenesis, metabolism, and neuronal differentiation are among the main biological processes affected by transfection of this miRNA combination. In conclusion, we demonstrated the value of using combinations of neurogenic miRNAs to disrupt cancer phenotypes and glioma stem cell growth. The synergistic effect of these three miRNA amplified the repression of oncogenic factors and the effect on cancer relevant pathways. Future therapeutic approaches would benefit from utilizing miRNA combinations, especially when targeting cancer-initiating cell populations.

Indexed as

glioblastomamiR-124miR-128miR-137miRNAneuroblastoma

Identifiers

PMID33466745
PMCPMC7831004
OpenAlexW3113300659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.